Advertisement

PharmacoEconomics & Outcomes News

, Volume 844, Issue 1, pp 13–13 | Cite as

Cladribine cost-saving option in highly active relapsing MS

Clinical study
  • 2 Downloads

Reference

  1. Mankinen P, et al. Cost Assessment Modelling of Treatments for Highly Active Relapsing Multiple Sclerosis. Advances in Therapy : 23 Dec 2019. Available from: URL: http://doi.org/10.1007/s12325-019-01186-z

Copyright information

© Springer International Publishing AG 2020

Personalised recommendations